(Reuters) – Biohaven has met the primary purpose in a examine evaluating its drug in sufferers with an inherited illness that primarily impacts the mind, the corporate stated on Monday.
The drug troriluzole confirmed clinically significant slowing of illness development in sufferers with Spinocerebellar Ataxia (SCA), the corporate stated.
The neurodegenerative illness impacts about 15,000 folks in the USA, based on firm estimates.
Shares of Biohaven, rose greater than 20% in premarket buying and selling.
